VivoSeq
Neurology

Encephalopathy

104

Pipeline Programs↗

24

Active Trials↗

45

Companies Involved↗

Encephalopathy is a highly competitive landscape with 104 programs across 45 companies. The most active players are Parkedale, Jiangsu Topcel-KH Pharmaceutical Co., Ltd., AbbVie. 15 therapies are approved with 12 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

71/100

Pipeline Velocity

27/100

Mech. Concentration

13/100

Completion Rate

78/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

P

Parkedale

1 program

Phase 1J

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

1 program

Phase 1AbbVie logo

AbbVie

1 program

Phase 1Amgen logo

Amgen

3 programs

Phase 2O

Ocera Therapeutics

2 programs

Phase 2A

Avid Radiopharmaceuticals

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical25

Thiamine

Universiti Kebangsaan Malaysia Medical Centre

Dexamethasone

Aspen Global Incorporated

Dexmedetomidine

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Standard Medical Therapy

Post Graduate Institute of Medical Education and Research, Chandigarh

Ibuprofen

Kenvue Brands

Phase 18

Colistin

Parkedale

Mesenchymal Stem Cells

Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Lactobacillus GG

Virginia Commonwealth University

Fosigotifator

AbbVie

Hydrogen Gas (h2)

Boston Children's Hospital

Phase 244

Sodium Benzoate

Liminal BioSciences Ltd.

Axicabtagene Ciloleucel

Gilead

Sildenafil

Viatris Specialty LLC

Cyclophosphamide

Baxter Healthcare Corporation

Darbepoetin Alfa

Amgen

Phase 312

Nitazoxanide

Romark Laboratories L.C.

Rifaximin

Salix

Erythropoietin

Wim Janssens

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

VSL#3

CD Pharma India Pvt. Ltd.

Approved15

Metformin

EMD Serono

Lactulose

Solvay Pharmaceuticals

Mannitol

B. Braun Medical Inc.

Levocarnitine

Leadiant Biosciences, Inc.

Polyethylene Glycol

Bayer

Analysis

Modality Breakdown

94%

Small molecule

111 of 118 classified programs — the dominant modality here.

6%ALL OTHERSCell therapy33%Peptide22%Monoclonal antibody1<1%Gene therapy1<1%

Small molecule leads; the ring shows all 118 classified programs, each share of the total. Modality classified for 100% of 136 pipeline programs.

Analysis

Trial Status

152

clinical trials

Completed77 · 51%
Unknown status29 · 19%
Terminated12 · 8%
Recruiting12 · 8%
Withdrawn9 · 6%
Active, not recruiting7 · 5%
Other6 · 4%

Clinical Trials

Trial Activity

152 trials

Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose
Recruiting·—·Phase 4·NCT04073290·238 enrolled
Human Albumin Infusion in Liver Cirrhosis and Overt Hepatic Encephalopathy (HACHE)
Recruiting·GGeneral Hospital of Shenyang Military Region·N/A·NCT06483737·174 enrolled
Hepatic Encephalopathy and Albumin Lasting Cognitive Improvement
Recruiting·HHunter Holmes Mcguire Veteran Affairs Medical Center·Phase 2·NCT06052176·30 enrolled
Efficacy and Safety of Nitazoxanide in Preventing Recurrence of Hepatic Encephalopathy
Recruiting·TTanta University·Phase 3·NCT04161053·60 enrolled
Darbepoetin in Neonatal Encephalopathy Trial
Recruiting·IImperial College London·Phase 2·NCT04432662·150 enrolled
Erythropoietin for Neonatal Encephalopathy in LMIC (EMBRACE Trial)
Recruiting·IImperial College London·Phase 3·NCT05395195·504 enrolled
Fecal Microbiota Transplantation by Oral Capsules for Hepatic Encephalopathy Treatment
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 1·NCT06368895·60 enrolled
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of RLS-0071 in Newborns With Moderate or Severe Hypoxic-Ischemic Encephalopathy Undergoing Therapeutic Hypothermia
Recruiting·RReAlta Life Sciences, Inc.·Phase 2·NCT05778188·42 enrolled
Role of Citicoline in Treatment of Neonates With Hypoxic Ischemic Encephalopathy
Recruiting·—·Phase 1·NCT06522581·200 enrolled
Treatment of Neonatal Encephalopathy With Oral Sildenafil Suspension to Repair Brain Injury Secondary to Birth Asphyxia
Recruiting·—·Phase 2·NCT06098833·60 enrolled
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
Recruiting·PPharmazz, Inc.·Phase 2·NCT05514340·40 enrolled
Neonatal Hypoxic Ischemic Encephalopathy : Safety and Feasibility Study of a Curative Treatment With Autologous Cord Blood Stem Cells
Recruiting·AAssistance Publique Hopitaux De Marseille·Phase 1/2·NCT02881970·20 enrolled
Single Patient Investigational Treatment for Cree Leukoencephalopathy
Active, not recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·N/A·NCT07300397·1 enrolled
Research Study for Single-Patient Treatment of Cree Leukoencephalopathy/Vanishing White Matter Disease
Active, not recruiting·MMcGill University Health Centre/Research Institute of the McGill University Health Centre·Phase 1·NCT07272525·1 enrolled
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Active, not recruiting·BBausch Health Americas, Inc.·Phase 3·NCT05297448·466 enrolled
Page 1 of 11

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)